An interventional study of Dynamic fluoroscopy in Atrial Fibrillation, sponsored by French Cardiology Society. Recruiting at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by French Cardiology Society · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 317 studies in Atrial Fibrillation with a site in France — 63 open to participants now, 87 under way, 5 of them phase 3. Atrial Fibrillation · France.
Among the 317 studies in Atrial Fibrillation with a site in France, this one is the 96th largest by planned enrollment of the 193 interventional ones that give a count, is one of 15 that started in 2026, is one of 117 with no phase, reaches primary completion later than 41 of the 86 other live ones, and was the 305th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →63 of the 317 studies in Atrial Fibrillation with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Poitiers University Hospital · Sites in France
Ages 18–90
Volta Medical · Sites in France
Ages 18+
Oslo University Hospital · Sites in France, United States, Belgium and 7 more countries
Ages 18+
Boston Scientific Corporation · Sites in France, Belgium, Croatia and 2 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
317 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 12 · Phase 3 42 · Phase 4 24
First in 1999; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 250 across the 193 interventional studies, 250 across the 123 observational. Of the 205 that completed or were terminated, 61 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 317 have an industry lead sponsor. The 10 most frequent:
French Cardiology Society is the lead sponsor of 85 studies on the registry; 16 are open to participants now.
French Cardiology Society has 5 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
23 of the studies in Atrial Fibrillation with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT05773638University Hospital, BrestCardiovascular and Venous Thromboembolism Disease in Patients with Von Willebrand Disease in the French West | 2026-12-26 |
| NCT05777551Clinica MediterraneaAF Ablation With High Power Short Duration RF | 2026-12-31 |
| NCT05790707Poitiers University HospitalEfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment | 2027-01 |
| NCT07116525Biosense Webster, Inc.A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter | 2027-02-07 |
Add all 23 to your calendar (.ics) → With an account.
Among the 317 studies in Atrial Fibrillation with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pulsed Field Ablation (PFA) represents a recent advance in the treatment of atrial fibrillation (AF), with a safety profile potentially superior to traditional thermal techniques, such as radiofrequency or cryoablation. Its mechanism of action allows tissue selectivity which in theory limits damage to extracardiac structures. However, several cases of right diaphragmatic paralysis have been reported in the literature after PFA, particularly during applications on the right pulmonary veins, near the right phrenic nerve. The available data are from studies without specific diaphragmatic monitoring. The diagnosis of diaphragmatic paralysis is most often based on chest X-ray, a static examination of limited sensitivity, especially for the detection of incomplete paralysis. To date, no prospective multicentre study has evaluated the incidence of diaphragmatic paralysis after PFA with systematic dynamic imaging, such as fluoroscopy, considered the gold standard for the diagnosis of unilateral paralysis.
The current study, DEFINE-PFA, aims to include 250 patients spread over 9 centres (France, New-Zealand and Canada). Each patient will benefit from dynamic fluoroscopy before and after the procedure. A new fluoroscopy will be performed at 3 months in patients with a significant reduction (>15%) in postoperative diaphragmatic amplitude.
The primary endpoint is based on the appearance of post-procedure inter-hemi diaphragmatic asymmetry, rather than a simple decrease in craniocaudal amplitude compared to the reference fluoroscopy. Indeed, the absolute diaphragmatic amplitude is highly dependent on the examination conditions, in particular the degree of cooperation of the patient and the intensity of forced inspiration, making inter-examination comparisons unreliable. Conversely, the simultaneous comparison of the two hemidiaphragms during the same inspiratory cycle makes it possible to attenuate these biases by using the contralateral hemidiaphragm as a stable internal reference. Pre-procedure fluoroscopy is nevertheless systematically performed in order to check the absence of basic asymmetry.
The threshold of 15% inter-hemi diaphragmatic asymmetry was empirically retained, in the absence of a cut-off validated in the literature for dynamic fluoroscopy. In diaphragmatic ultrasound, asymmetry is generally considered significant for differences in amplitude > 20% between the two hemi domes, but these measurements are performed successively, which makes them sensitive to variations between respiratory cycles. Conversely, fluoroscopy allows simultaneous observation of the two hemidiaphragms during the same respiratory cycle, offering a more reliable comparison. This threshold aims to detect significant asymmetry while minimizing false positives related to physiological variability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evidence of diaphragmatic paralysis on the pre-procedure fluoroscopy loop, defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Systematic observation of an additional examination (dynamic fluoroscopy) performed before and after a Pulsed Field Ablation procedure, as part of the standard management of atrial fibrillation.
Procedure: Dynamic fluoroscopy
Fluoroscopic loop recording or continuous digital scopy of the thoracic window, over at least one complete breathing cycle at maximum amplitude.
Diaphragmatic paralysis
Post-procedural occurrence of diaphragmatic contraction asymmetry, defined as a ≥15% reduction in the cranio-caudal amplitude of a hemi-diaphragm, relative to the contralateral side, measured by dynamic fluoroscopy during a forced breathing cycle, and absent on pre-procedure fluoroscopy.
Time frame: Day1: Before the Pulsed Field Ablation and after the Pulsed Field Ablation (at hospital discharge between 2 and 30 hours after ablation, according to a rigorously standardized protocol in all participating centres)
Rate of complete or partial recovery of diaphragmatic function at 3 months.
For patient with diaphragmatic paralysis observed at inclusion visit, diaphragmatic contraction asymmetry evaluation will be redo after 3 months.
Time frame: At 3 months
Evaluation of symptoms associated with diaphragmatic paralysis
Presence / absence of symptoms : dyspnea, discomfort on inspiration, decreased physical capacity, sleep disturbances.
Time frame: Day 1, at 3 months
Evaluation of the efficiency of the procedure
Comparison, between patients who experienced diaphragmatic paralysis after ablation and those who did not, of the duration of the procedure (in minutes), the duration of the endoscopy (in minutes), the total number of applications and the type of catheter used.
Time frame: Day1
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for May 2027, 11 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 11 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
French Cardiology Society